Overview

Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer

Status:
Terminated

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study

Phase:

Phase 2

Details

Lead Sponsor:

Maria Constantinou

Treatments:

Naltrexone